Insider: Lonial Sagar Director - TG THERAPEUTICS, INC.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 94,061 | 0 | 94,061 |
| Value | $3,339,165.50 | $0.00 | $3,339,165.50 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 09/11/2025 | DDS | 20,852 | Direct | COM | $32.24 | $672,268.48 | 94,061 |
| 11/11/2024 | DDS | 5,000 | Direct | COM | $30.44 | $152,200.00 | 100,195 |
| 06/20/2024 | DDS | 16,348 | Direct | COM | $16.87 | $275,790.76 | 105,195 |
| 06/17/2024 | DDS | 9,585 | Direct | COM | $16.39 | $157,098.15 | 99,293 |
| 03/13/2024 | DDS | 5,000 | Direct | COM | $15.94 | $79,675.00 | 108,878 |
| 06/23/2023 | DDS | 34,854 | Direct | COM | $23.37 | $814,537.98 | 93,878 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research